Catalyst Pharmaceuticals (CPRX) Downgraded by BidaskClub

Catalyst Pharmaceuticals (NASDAQ:CPRX) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

Several other equities analysts have also weighed in on CPRX. ValuEngine lowered Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 8th. HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, August 9th. Oppenheimer set a $6.00 target price on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 9th. Zacks Investment Research raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 target price on the stock in a research note on Monday, August 13th. Finally, Piper Jaffray Companies began coverage on Catalyst Pharmaceuticals in a report on Friday, September 7th. They issued an “overweight” rating and a $5.00 price target for the company. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $5.65.

NASDAQ:CPRX opened at $2.23 on Wednesday. Catalyst Pharmaceuticals has a 1-year low of $2.18 and a 1-year high of $4.29.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). As a group, equities analysts anticipate that Catalyst Pharmaceuticals will post -0.3 EPS for the current year.

Several institutional investors have recently made changes to their positions in the business. Acadian Asset Management LLC acquired a new position in shares of Catalyst Pharmaceuticals in the second quarter valued at approximately $476,000. Rhumbline Advisers grew its holdings in Catalyst Pharmaceuticals by 34.7% during the 2nd quarter. Rhumbline Advisers now owns 90,725 shares of the biopharmaceutical company’s stock worth $283,000 after acquiring an additional 23,383 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Catalyst Pharmaceuticals by 15.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 274,813 shares of the biopharmaceutical company’s stock worth $858,000 after acquiring an additional 37,388 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in Catalyst Pharmaceuticals by 12.7% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 208,404 shares of the biopharmaceutical company’s stock worth $651,000 after acquiring an additional 23,500 shares in the last quarter. Finally, GSA Capital Partners LLP grew its holdings in Catalyst Pharmaceuticals by 295.7% during the 2nd quarter. GSA Capital Partners LLP now owns 380,605 shares of the biopharmaceutical company’s stock worth $1,187,000 after acquiring an additional 284,409 shares in the last quarter. Institutional investors own 49.61% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.

See Also: Cost of Capital

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply